Tharimmune (THAR) Competitors $1.41 +0.05 (+3.68%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$1.41 0.00 (0.00%) As of 03/28/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. QNTM, BLRX, TLPH, PMCB, PHXM, TXMD, INDP, SLXN, GELS, and APLMShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Quantum Biopharma (QNTM), BioLineRx (BLRX), Talphera (TLPH), PharmaCyte Biotech (PMCB), PHAXIAM Therapeutics (PHXM), TherapeuticsMD (TXMD), Indaptus Therapeutics (INDP), Silexion Therapeutics (SLXN), Gelteq (GELS), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Quantum Biopharma BioLineRx Talphera PharmaCyte Biotech PHAXIAM Therapeutics TherapeuticsMD Indaptus Therapeutics Silexion Therapeutics Gelteq Apollomics Quantum Biopharma (NASDAQ:QNTM) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, QNTM or THAR? Quantum Biopharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Is QNTM or THAR more profitable? Quantum Biopharma's return on equity of -84.21% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -84.21% -62.63% Tharimmune N/A -167.63%-130.18% Do analysts prefer QNTM or THAR? Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 1,105.67%. Given Tharimmune's stronger consensus rating and higher probable upside, analysts plainly believe Tharimmune is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has preferable earnings & valuation, QNTM or THAR? Quantum Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$17.90M-$15.41-0.56TharimmuneN/AN/A-$9.32M-$9.74-0.14 Does the MarketBeat Community favor QNTM or THAR? Tharimmune received 2 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformQuantum BiopharmaN/AN/ATharimmuneOutperform Votes2100.00% Underperform VotesNo Votes Do institutionals & insiders hold more shares of QNTM or THAR? 1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 2.4% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor QNTM or THAR? In the previous week, Quantum Biopharma had 8 more articles in the media than Tharimmune. MarketBeat recorded 12 mentions for Quantum Biopharma and 4 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.85 beat Quantum Biopharma's score of -0.28 indicating that Tharimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTharimmune beats Quantum Biopharma on 10 of the 15 factors compared between the two stocks. Remove Ads Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.73M$6.91B$5.63B$7.83BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-0.147.2923.6818.75Price / SalesN/A218.91383.9790.87Price / CashN/A65.6738.1734.64Price / Book0.016.386.894.23Net Income-$9.32M$142.34M$3.20B$247.47M7 Day Performance-7.84%-5.83%-3.57%-3.56%1 Month Performance-1.40%-7.55%1.50%-5.81%1 Year Performance-78.15%-11.06%9.32%-0.96% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.9357 of 5 stars$1.41+3.7%$17.00+1,105.7%-78.1%$2.73MN/A-0.142Earnings ReportShort Interest ↓QNTMQuantum BiopharmaN/A$5.86+5.6%N/AN/A$11.25MN/A-0.38N/AEarnings ReportNews CoverageGap UpBLRXBioLineRx2.8087 of 5 stars$3.34-2.3%$360.00+10,678.4%-93.2%$11.12M$21.99M-0.3840Gap DownTLPHTalphera2.1041 of 5 stars$0.64+0.7%$4.33+573.2%-43.1%$10.96M$281,000.00-0.9319Short Interest ↑PMCBPharmaCyte Biotech1.3589 of 5 stars$1.56-0.6%N/A-44.3%$10.71MN/A2.944Short Interest ↑Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049TXMDTherapeuticsMD0.8893 of 5 stars$0.91+5.4%N/A-57.1%$10.52M$1.60M0.00420Upcoming EarningsShort Interest ↓Gap DownINDPIndaptus Therapeutics3.7564 of 5 stars$0.71+8.0%$8.50+1,092.1%-73.7%$10.29MN/A-0.426Gap UpHigh Trading VolumeSLXNSilexion TherapeuticsN/A$1.19+6.3%$5.00+320.2%N/A$10.01MN/A0.00N/AGELSGelteqN/A$1.06+1.4%N/AN/A$10.00MN/A0.00N/AAPLMApollomics2.568 of 5 stars$9.10-4.2%$200.00+2,097.8%-89.8%$9.89M$1.22M0.0045Gap Up Remove Ads Related Companies and Tools Related Companies Quantum Biopharma Competitors BioLineRx Competitors Talphera Competitors PharmaCyte Biotech Competitors PHAXIAM Therapeutics Competitors TherapeuticsMD Competitors Indaptus Therapeutics Competitors Silexion Therapeutics Competitors Gelteq Competitors Apollomics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
